Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent released polypeptide (GIP) receptor , is showing promising data in early clinical studies. Ongoing inquiry indicates that retatrutide may offer substantial improvements for individuals with obesity, particularly regar